Moderator
Takashi Fukuda, PhD, National Institute of Public Health, Wako-shi, Japan
Speakers
Takeru Shiroiwa, MPH, PhD, National Institute of Public Health, Wako, Saitama, Japan; Shunya Ikeda, MSc, PhD, MD, International University of Health and Welfare, Narita, Japan; Akira Yuasa, PhD, Pfizer Japan Inc, Tokyo, Japan
Presentation Documents
Purpose
The objective of this session is to share the progress and current issues of the Japanese new Health Technology Assessment (HTA) system, which started in 2019 from the perspectives of the government, academia and industry.
Description
The new HTA system, which is the cost-effectiveness evaluation of pharmaceuticals and medical devices, officially started in 2019. During 6 years, over 40 products were assessed, and some of which resulted in reimbursement price adjustment. In this session, after the brief introduction of the system by the moderator (5 min.), Dr. Shiroiwa will introduce the background, progress and current issues of the system including the use of real world data from the perspective of the public assessor (15 min.). Dr. Ikeda will make a presentation about the issues and future possible directions from the academic perspective (15 min.). Finally, Dr. Yuasa will provide the views about the system from a pharmaceutical company or industry perspective (15 min.). The session will be concluded by questions and discussions between audience and panel members (10 min.). This session may benefit policymakers and HTA agencies, as well as academia and industry.
Code
11
Topic Subcategory
Health & Insurance Records Systems